S&P 500 Futures
(-0.05%) 5 305.50 points
Dow J Futures
(-0.02%) 40 137 points
Nasdaq Futures
(-0.06%) 18 493 points
Oil
(0.43%) $81.70
Gas
(-0.93%) $1.702
Gold
(1.16%) $2 216.10
Silver
(-0.78%) $24.56
Platinum
(-0.28%) $907.15
USD/EUR
(0.36%) $0.927
USD/NOK
(0.68%) $10.84
USD/GBP
(0.24%) $0.793
USD/RUB
(-0.08%) $92.37

Realtime updates for Eisai Co., Ltd. [ESALF]

Exchange: OTC Sector: Healthcare Industry: Drug Manufacturersā€”Specialty & Generic
Last Updated27 Mar 2024 @ 15:49

0.12% $ 42.35

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 15:49):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...

Stats
Today's Volume 670.00
Average Volume 544.00
Market Cap 12.16B
EPS $9.72 ( 2023-11-06 )
Last Dividend $0.603 ( 2023-03-30 )
Next Dividend $0 ( N/A )
P/E 40.72
ATR14 $0 (0.00%)

Eisai Co., Ltd. Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eisai Co., Ltd. Financials

Annual 2023
Revenue: $744.40B
Gross Profit: $543.48B (73.01 %)
EPS: $193.31
Q3 2023
Revenue: $177.70B
Gross Profit: $138.82B (78.12 %)
EPS: $20.81
Q2 2023
Revenue: $176.62B
Gross Profit: $140.19B (79.38 %)
EPS: $19.73
Q1 2023
Revenue: $196.94B
Gross Profit: $153.02B (77.70 %)
EPS: $70.92

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.555
(N/A)
$0
(N/A)
$0.603
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.99 - Decrease likely (20.12%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.784 2014-03-27
Last Dividend $0.603 2023-03-30
Next Dividend $0 N/A
Payout Date 2018-05-24
Next Payout Date N/A
# dividends 18 --
Total Paid Out $11.60 --
Avg. Dividend % Per Year 0.00% --
Score 2.79 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 3.99
Div. Directional Score 7.04 --
Next Divdend (Est)
(2024-09-23)
$0 Estimate 3.61 %
Dividend Stability
0.29 Very Poor
Dividend Score
2.79
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
VLEEY Ex Dividend Junior 2023-05-25 Annually 0 0.00%
MRPLY Ex Dividend Junior 2023-07-13 Annually 0 0.00%
CUYTY Ex Dividend Junior 2023-09-29 Annually 0 0.00%
SMSMY Ex Dividend Junior 2023-10-02 Annually 0 0.00%
HNFSB Ex Dividend Knight 2023-08-09 Quarterly 0 0.00%
BHRB Ex Dividend Knight 2023-08-14 Quarterly 0 0.00%
YKLTF Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
OEZVY Ex Dividend Knight 2023-05-05 Annually 0 0.00%
EDNMY Ex Dividend Junior 2023-06-05 Annually 0 0.00%
TBLMY Ex Dividend Junior 2023-07-06 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06061.5008.7910.00[0 - 0.5]
returnOnAssetsTTM0.03461.2008.8510.00[0 - 0.3]
returnOnEquityTTM0.05461.500-0.504-0.756[0.1 - 1]
payoutRatioTTM1.011-1.00010.00-10.00[0 - 1]
currentRatioTTM2.380.8003.102.48[1 - 3]
quickRatioTTM1.6970.8004.723.78[0.8 - 2.5]
cashRatioTTM1.0251.5005.428.12[0.2 - 2]
debtRatioTTM0.127-1.5007.89-10.00[0 - 0.6]
interestCoverageTTM25.361.0001.7191.719[3 - 30]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 20]
debtEquityRatioTTM0.203-1.5009.19-10.00[0 - 2.5]
grossProfitMarginTTM0.7891.0000.1760.176[0.2 - 0.8]
operatingProfitMarginTTM0.07901.000-0.419-0.419[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3721.0009.049.04[0.2 - 2]
assetTurnoverTTM0.5720.8009.527.62[0.5 - 2]
Total Score10.08

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM40.471.0006.010[1 - 100]
returnOnEquityTTM0.05462.50-0.324-0.756[0.1 - 1.5]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 30]
dividendYielPercentageTTM0.02601.5009.350[0 - 0.4]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
payoutRatioTTM1.0111.50010.00-10.00[0 - 1]
pegRatioTTM0.01721.500-3.220[0.5 - 2]
operatingCashFlowSalesRatioTTM0.08261.000-0.4340[0.1 - 0.5]
Total Score3.99

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators